Protalix BioTherapeutics Inc

Type: Company
Name: Protalix BioTherapeutics Inc (Protalix Biotherapeutics Inc)
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

Protalix loses half value in 1 year

Misfortunes never come singly: two days ago, after the end of trading, it was learned that the US Food and Drug Administration (FDA) had approved for marketing a competing drug for Protalix's flagship product. Yesterday, it was reported that another company ... [Published Globes - Aug 21 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 2 reports

Research and Markets: Global Lysosomal Storage Diseases Market 2014-2018: Key Vendors are Actelion Pharmaceuticals, …

DUBLIN--(BUSINESS WIRE)--Research and Markets ( http://www.researchandmarkets.com/research/5f7fvn/global_lysosomal ) has announced the addition of the "Global Lysosomal Storage Diseases Market 2014-2018" report to their offering.The Global Lysosomal ... [Published Yahoo! Finance - Aug 21 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

US nod for Genzyme's Gaucher pills

US regulators have issued a green light for Genzyme’s Gaucher disease capsules Cerdelga (eliglustat), offering patients the first oral first-line treatment for the rare genetic disorder.Following a priority review, the US Food and Drug Administration ... [Published Pharma Times - Aug 20 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 3 reports

Protalix BioTherapeutics Reaches New 12-Month Low at $2.35 (PLX)

Protalix BioTherapeutics (NYSE:PLX) shares reached a new 52-week low on Wednesday , reports. The stock traded as low as $2.35 and last traded at $2.43, with a volume of 627,535 shares trading hands. The stock had previously closed at $2.65.Separately, ... [Published American Banking News - Forex - Aug 20 2014]
First reported Aug 17 2014 - Updated Aug 17 2014 - 1 reports

ANALYSIS-'Plantibodies' drugs advance as big pharma stands aside

LOS ANGELES, Aug 17 (Reuters) - Biotech drug production techniques based on plants, which may prove to be faster, higher yielding and cheaper than current methods using mammalian cells, haven't caught on with the biggest pharmaceutical companies.The leading ... [Published CNBC - Aug 17 2014]
First reported Aug 17 2014 - Updated Aug 17 2014 - 1 reports

InsiderInsights.com Daily Round Up: 8/15/14

Summary Tables of the top insider purchases and sales filed with the SEC on 8/15/14, based on dollar value. Dollar values often do not equate with significance when it comes to insider trades. Proprietary Insider Company Ratings are further given for ... [Published Seeking Alpha - Aug 17 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

Thu: Perrigo leads rises

The market rose today, with Perrigo buoyed by good results and the major banks up as well.The Tel Aviv Stock Exchange rose today. The Tel Aviv 25 Index rose 0.24%, to 1,389.35 points; the Tel Aviv 100 Index rose 0.30%, to 1,239.45 points; and the BlueTech ... [Published Globes - Aug 14 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 3 reports

Investors look to Lighten Up on Shares of Protalix BioTherapeutics, Shares Down 5.9% (PLX)

Written on Wed, 08/13/2014 - 1:14pmBy Amy SchwartzProtalix BioTherapeutics ( AMEX:PLX ) is one of today's worst performing low-priced stocks, down 5.9% to $2.69 on 1.0x average daily volume. Protalix BioTherapeutics has traded 323,000 shares thus far ... [Published Comtex SmarTrend - Aug 13 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 2 reports

Protalix BioTherapeutics Short Interest Up 6.7% in July (PLX)

Protalix BioTherapeutics (NYSE:PLX) was the target of a large increase in short interest in July. As of July 31st, there was short interest totalling 5,921,103 shares, an increase of 6.7% from the July 15th total of 5,548,739 shares, ARN reports. Currently, ... [Published American Banking News - Aug 12 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Ebola outbreak puts spotlight on tobacco-based drug production

Over the past decade, plant-made drugs have generated plenty of chatter but have had little effect on commercial manufacturing, with the 2012 FDA approval of Pfizer ($PFE) and Protalix Biotherapeutics ($PLX) an isolated success. The approach was again ... [Published FiercePharmaManufacturing - Aug 06 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

Protalix BioTherapeutics Reaches New 1-Year Low at $3.03 (PLX)

Protalix BioTherapeutics (NYSE:PLX) reached a new 52-week low on Monday , ARN reports. The company traded as low as $3.03 and last traded at $3.04, with a volume of 259,380 shares trading hands. The stock had previously closed at $3.28.Several analysts ... [Published American Banking News - Aug 04 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 5 reports

Protalix names Shlomo Yanai chairman [Globes, Tel Aviv, Israel :: ]

July 25--Protalix Biotherapeutics Inc"The board of Protalix and myself are pleased to have Mr. Yanai join our board as chairman," Bronfeld said, "He brings extensive knowledge and vast experience from his years as CEO at Teva Pharmaceutical Industrie ... [Published BusinessWeek - Jul 24 2014]

Quotes

"The challenge has been to think about pricing in a way that"
"We see it having pretty broad applicability," Stewart said. "The cost of these drugs is a huge burden on healthcare systems in the first world, particularly drugs for oncology and chronic disease."
And in spite of the science blogger's claim that the new Ebola drug is "readily up-scalable", for the moment, there are " virtually no doses available ", according to the US CentersCenters for Disease Control and Prevention."
...The turnaround times of plant-made drugs are one reason they have attracted the interest of biodefense groups. "Producing antibodies in plants is faster and less expensive than traditional manufacturing" Mary Kate Hart, an immunology researcher who worked on Ebola antibodies for the U S Army, told Bloomberg

More Content

All (55) | News (39) | Reports (0) | Blogs (5) | Audio/Video (0) | Fact Sheets (2) | Press Releases (9)
sort by: Date | Relevance
Protalix loses half value in 1 year [Published Globes - Aug 21 2014]
Research and Markets: Global Lysosomal Storage ... [Published Yahoo! Finance - Aug 21 2014]
Global Lysosomal Storage Diseases Market 2014-2... [Published Individual.com - Aug 21 2014]
Protalix BioTherapeutics Reaches New 12-Month L... [Published American Banking News - Forex - Aug 20 2014]
Protalix BioTherapeutics Down 7.5%, Shar... [Published Financial News Network online - Aug 20 2014]
Protalix BioTherapeutics Down 7.5%, Shares Slid... [Published Individual.com - Aug 20 2014]
US nod for Genzyme's Gaucher pills [Published Pharma Times - Aug 20 2014]
U.S. FDA approves Sanofi's Gaucher disease drug... [Published Reuters - Aug 19 2014]
FDA okays Genzyme pill for Gaucher disease [Published Boston Globe - Aug 19 2014]
ANALYSIS-'Plantibodies' drugs advance as big ph... [Published CNBC - Aug 17 2014]
InsiderInsights.com Daily Round Up: 8/15/14 [Published Seeking Alpha - Aug 17 2014]
Thu: Perrigo leads rises [Published Globes - Aug 14 2014]
Investors look to Lighten Up on Shares of Prota... [Published Comtex SmarTrend - Aug 13 2014]
Protalix BioTherapeutics Down 5.9%, Shares Slid... [Published Individual.com - Aug 13 2014]
Investors look to Lighten Up on Shares of Prota... [Published Individual.com - Aug 13 2014]
Protalix BioTherapeutics Short Interest Up 6.7%... [Published American Banking News - Aug 12 2014]
Tyman PLC Price Target Cut to GBX 366 by Analys... [Published Mideast Time - Aug 12 2014]
Protalix BioTherapeutics Receives “Hold” Rating... [Published American Banking News - Aug 11 2014]
GMO tobacco Ebola drug under the spotlight [Published GMWatch.org - Aug 08 2014]
Trends in Single-Use Biomanufacturing [Published PharmTech.com - Aug 07 2014]
Ebola outbreak puts spotlight on tobacco-based ... [Published FiercePharmaManufacturing - Aug 06 2014]
Tobacco-derived 'plantibodies' enter the fight ... [Published Sharenet - Aug 06 2014]
Ebola Drug From Tobacco Part of Promising Plant... [Published Bisnis Indonesia - Aug 06 2014]
Protalix BioTherapeutics Reaches New 1-Year Low... [Published American Banking News - Aug 04 2014]
Shares of Protalix BioTherapeutics Has Fallen B... [Published Comtex SmarTrend - Aug 04 2014]
First Prescription Medicine Certified Kosher by... [Published Atascadero News - Jul 28 2014]
Sarepta science officer Krieg 'terminated' quietly [Published FierceBiotech - Jul 25 2014]
Keryx Announces Zerenex LT Phase 3 Results; Esp... [Published BioMedReports - Jul 25 2014]
Protalix names Shlomo Yanai chairman [Globes, T... [Published BusinessWeek - Jul 24 2014]
Protalix names Shlomo Yanai chairman [Published Globes - Jul 24 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
2nd Quarter Executive Turnover Remains Positive... [Published Management Turnover as Change Agent - Jul 17 2014]
Executive turnover continues in a positive direction despite a slowdown in a few of the key categories.  The trend in executive turnover continues to correlate with the continuing positive news related to job growth in the American economy and the declining ...
Research and Markets: Nerve Gas & Pesticide Poi... [Published Business Wire Manufacturing News - May 28 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zsmp3h/nerve_gas_and) has announced the addition of the "Nerve Gas & Pesticide Poisoning - Pipeline Review, H1 2014" report to their offering. This report provides ...
Research and Markets: Nerve Gas & Pesticide Poi... [Published Business Wire Health News - May 28 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zsmp3h/nerve_gas_and) has announced the addition of the "Nerve Gas & Pesticide Poisoning - Pipeline Review, H1 2014" report to their offering. This report provides ...
Australia's TGA approves Protalix's ELELYSO for... [Published PBR - News - May 23 2014]
The Australian Therapeutic Goods Administration (TGA) has approved Israel-based Protalix BioTherapeutics' ELELYSO (taliglucerase alfa) for injection as a long-term enzyme replacement therapy to treat Gaucher disease in both adult and pediatric patien ...
ClickSoftware Advances on New Clients: Israel O... [Published Bloomberg via Google News - Feb 09 2014]
ClickSoftware Advances on New Clients: Israel Overnight Bloomberg The Bloomberg Israel-US Equity Index of the largest Israeli companies traded in New York added 0.3 percent, led by Protalix BioTherapeutics Inc. SodaStream International Ltd., the ...
1

Press Releases

sort by: Date | Relevance
Protalix Announces New Data on ELELYSO(TM) (tal... [Published GlobeNewswire: Advertising News - Jun 27 2014]
Protalix BioTherapeutics Announces New Data on ... [Published GlobeNewswire: Advertising News - Jun 23 2014]
Protalix BioTherapeutics Initiates Phase II Stu... [Published GlobeNewswire: Advertising News - Jun 18 2014]
Protalix BioTherapeutics' President and Chief E... [Published GlobeNewswire: Acquisitions News - Jun 13 2014]
Protalix Announces ELELYSO(TM) (taliglucerase a... [Published GlobeNewswire: Advertising News - May 30 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.